Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604520 · ClinicalTrials.gov registry record · Phase 2
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
A Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06604520 is a Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 50 participants, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06604520, a Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are: 1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD? 2. Do mood symptoms and cognition improve following treatment with vortioxetine? Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment. Participants will: * Undergo a screening visit that involves clinical assessments and laboratory tests * Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine * Undergo memory and problem-solving tests before starting treatment with vortioxetine * Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist * Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine
Conditions Studied
Interventions
- DRUG Vortioxetine
Study Locations (1)
Maryland
- The Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06604520
The ClinicalTrials.gov registry entry for NCT06604520 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (96% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 1 intervention - of which Vortioxetine is the first listed.
NCT06604520 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06604520 about?
NCT06604520 is a clinical study titled "Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia". The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are: 1. Do individuals with mood symptoms and bvFTD have brain changes and c...
What is the current status of trial NCT06604520?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-03-20. Estimated completion is 2029-09-01.
What conditions does trial NCT06604520 study?
This clinical trial studies the following conditions: Frontotemporal Dementia, Frontotemporal Degeneration, Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Dementia (FTD).
What interventions are being tested in trial NCT06604520?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT06604520?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06604520 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frontotemporal Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
ACTIVE NOT RECRUITING · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.